<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347526</url>
  </required_header>
  <id_info>
    <org_study_id>17-0222</org_study_id>
    <nct_id>NCT03347526</nct_id>
  </id_info>
  <brief_title>A Novel Approach to Infantile Spasms</brief_title>
  <official_title>A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Epilepsy Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Therapuetics, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to assess the efficacy of Cosyntropin Injectable Suspension, 1 mg/mL
      compared to vigabatrin. Additionally, this study proposes to determine efficacy of
      combination therapy of Cosyntropin Injectable Suspension, 1 mg/mL and vigabatrin to
      monotherapy Cosyntropin Injectable Suspension, 1mg/mL in children with new onset infantile
      spasms (IS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized trial comparing 3 treatment arms:

        1. Cosyntropin Injectable Suspension, 1 mg/mL

        2. Vigabatrin

        3. Combination of both these therapies, Cosyntropin Injectable Suspension, 1 mg/mL and
           vigabatrin for treatment of new onset infantile spasms. Outcome measures include
           resolution of clinical spasms, improvement of hypsarrhythmia as well as longer term
           outcomes of development and subsequent seizures.

      The data is expected to demonstrate greater efficacy with Cosyntropin Injectable Suspension,
      1 mg/mL than vigabatrin for the treatment of IS.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study on enrollment hold as a precaution per the pharmaceutical company.
  </why_stopped>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Blinded outcome measure</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>A comparison of Cosyntropin Injectable Suspension and Vigabatrin on the proportion of subjects who become spasm-free as defined by a) and b).</measure>
    <time_frame>2 weeks</time_frame>
    <description>a) Resolution of hypsarrhythmia via video electroencephalogram (EEG), and b) Resolution of clinical spasms via video EEG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A comparison of combination therapy and Cosyntropin Injectable Suspension alone (monotherapy) on the proportion of subjects who become spasm-free as defined by a) and b)</measure>
    <time_frame>Day 14-42</time_frame>
    <description>a) Resolution of clinical spasms for 48 hours at 2 weeks sustained until day 42, and b) Resolution of hypsarrhythmia via video EEG at 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A comparison between combination therapy and Cosyntropin Injectable Suspension alone (monotherapy) on the proportion of subjects who become seizure free at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in proportion of subjects who are seizure free between 5 and 6 months after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between combination therapy and Cosyntropin Injectable Suspension alone (monotherapy).</measure>
    <time_frame>18 months chronological age</time_frame>
    <description>A comparison between combination therapy and Cosyntropin Injectable Suspension alone (monotherapy) on developmental scores as measured by the Adaptive Behavior Assessment System (ABAS III) at 18 months chronological age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between combination therapy and Cosyntropin Injectable Suspension alone (monotherapy).</measure>
    <time_frame>18 months chronological age</time_frame>
    <description>A comparison between combination therapy and Cosyntropin Injectable Suspension alone (monotherapy) on developmental scores as measured by the Vineland II at 18 months chronological age.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Infantile Spasm</condition>
  <arm_group>
    <arm_group_label>Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cosyntropin Injectable Suspension, 1 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigabatrin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin Injectable Suspension, 1 mg/mL</intervention_name>
    <description>Injectable</description>
    <arm_group_label>Cosyntropin Injectable Suspension, 1 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin</intervention_name>
    <description>Injectable + oral solution</description>
    <arm_group_label>Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>oral</description>
    <arm_group_label>Vigabatrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New onset infantile spasms

          -  Age &gt; 2 months

          -  Age&lt; 2 years

          -  Hypsarrhythmia on video-EEG

          -  Normal renal function

        Exclusion Criteria:

          -  Prior treatment given for infantile spasms

          -  Diagnosis of Ohtahara syndrome or Early Myoclonic Epilepsy

          -  Absence of hypsarrhythmia

          -  Inability for the parent or caregiver to provide consent

          -  Inability for the parent or caregiver to complete seizure diary

          -  Diagnosis of:

               -  scleroderma,

               -  osteoporosis,

               -  recent systemic fungal infections,

               -  ocular herpes simplex,

               -  recent surgery,

               -  history of or the presence of a peptic ulcer,

               -  congestive heart failure,

               -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly G. Knupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Scottish Rite</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vigabatrin</keyword>
  <keyword>Cosyntropin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

